Nausea and vomiting during high-dose interleukin-2 (HD IL-2) therapy.

被引：0
|
作者：
Fesler, Mark
Chu, Melinda Bernabe
Armbrecht, Eric
Fosko, Scott
Hsueh, Eddy C.
Richart, John M.
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
[2] St Louis Univ, Ctr Outcomes Res, St Louis, MO 63103 USA
[3] St Louis Univ, Dept Dermatol, St Louis, MO 63103 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20661
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry
    Clark, Joseph
    Morse, Michael
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] ANGIONEUROTIC-EDEMA AND URTICARIA DURING THERAPY WITH INTERLEUKIN-2 (IL-2)
    BAARS, JW
    WAGSTAFF, J
    HACK, CE
    WOLBINK, GJ
    EERENBERGBELMER, AJM
    PINEDO, HM
    ANNALS OF ONCOLOGY, 1992, 3 (03) : 243 - 244
  • [23] A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.
    Buchbinder, Elizabeth Iannotti
    Dutcher, Janice P.
    Perritt, Jessica C.
    Clark, Joseph
    Holtan, Shernan G.
    Kirkwood, John M.
    Curti, Brendan D.
    Lao, Christopher D.
    Kaufman, Howard
    Fishman, Mayer N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] EOSINOPHILIC MYOCARDITIS ASSOCIATED WITH HIGH-DOSE INTERLEUKIN-2 THERAPY
    SCHUCHTER, LM
    HENDRICKS, CB
    HOLLAND, KH
    SHELTON, BK
    HUTCHINS, GM
    BAUGHMAN, KL
    ETTINGER, DS
    AMERICAN JOURNAL OF MEDICINE, 1990, 88 (04): : 439 - 440
  • [25] REVERSIBLE CARDIOMYOPATHY AFTER HIGH-DOSE INTERLEUKIN-2 THERAPY
    GOEL, M
    FLAHERTY, L
    LAVINE, S
    REDMAN, BG
    JOURNAL OF IMMUNOTHERAPY, 1992, 11 (03): : 225 - 229
  • [26] Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
    Batten, Julia Anne
    Samlowski, Wolfram E.
    Parikh, Kinjal
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Tantravahi, Srinivas Kiran
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] INTERLEUKIN-2 (IL-2) IMMUNOTHERAPY
    MACEY, MG
    JOHNSTON, DH
    MEDICAL LABORATORY SCIENCES, 1990, 47 (03): : 220 - 225
  • [28] High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study
    HC Toh
    SL McAfee
    R Sackstein
    P Multani
    BF Cox
    R Garcia-Carbonero
    C Colby
    TR Spitzer
    Bone Marrow Transplantation, 2000, 25 : 19 - 24
  • [29] NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma-Efficacy and biomarker study
    Ashraf, Madeeha
    Kirkwood, John M.
    Ernstoff, Marc S.
    Abdul-Hassan, Hussein Tawbl
    Frankel, Paul Henry
    Ruel, Nora
    Kendra, Karl Lynn
    Olencki, Thomas
    Khushalani, NIkhil I.
    Logan, Theodore F.
    Margolin, Kim Allyson
    Chen, Alice P.
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] LOBULAR PANNICULITIS AFTER SUBCUTANEOUS ADMINISTRATION OF INTERLEUKIN-2 (IL-2), AND ITS EXACERBATION DURING INTRAVENOUS THERAPY WITH IL-2
    BAARS, JW
    COENEN, JLLM
    WAGSTAFF, J
    VANDERVALK, P
    PINEDO, HM
    BRITISH JOURNAL OF CANCER, 1992, 66 (04) : 698 - 699
12345